Ronald G Collman Selected Research

Ronald G Collman Research Topics

Disease

26	Infections 03/2024 - 07/2002
10	COVID-19 02/2024 - 01/2021
8	HIV Infections (HIV Infection) 12/2020 - 01/2003
7	Inflammation (Inflammations) 12/2022 - 11/2003
7	Acquired Immunodeficiency Syndrome (AIDS) 01/2021 - 10/2005
5	Sarcoidosis (Schaumann Disease) 12/2021 - 10/2015
5	Dysbiosis 04/2021 - 10/2018
3	Neoplasms (Cancer) 01/2022 - 01/2019
3	Tobacco Use Disorder (Nicotine Dependence) 12/2020 - 01/2019
3	Tuberculosis (Tuberculoses) 05/2015 - 06/2014
3	Viremia 02/2013 - 01/2008
3	Dementia (Dementias) 12/2009 - 08/2006
2	Severe Acute Respiratory Syndrome 09/2022 - 01/2022
2	Hematologic Neoplasms (Hematological Malignancy) 12/2021 - 03/2021
2	Disease Progression 12/2020 - 01/2011
2	Lung Diseases (Lung Disease) 11/2019 - 04/2016
2	Periodontitis 05/2019 - 01/2019
2	Critical Illness (Critically Ill) 05/2019 - 01/2019
2	Virus Diseases (Viral Diseases) 01/2019 - 12/2008
2	Neurocognitive Disorders (Clerambault Syndrome) 10/2016 - 10/2015
1	Lymphoma (Lymphomas) 02/2024
1	Primary Graft Dysfunction 12/2022
1	Human Influenza (Influenza) 01/2022
1	Reinfection 01/2022
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022
1	Periodontal Diseases (Periodontal Disease) 01/2022
1	Obesity 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2022
1	Lymphadenopathy 12/2021
1	Pulmonary Sarcoidosis 12/2021
1	Communicable Diseases (Infectious Diseases) 05/2021
1	Persistent Infection 03/2021
1	Sepsis (Septicemia) 03/2021
1	Cross Infection (Nosocomial Infection) 02/2019

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 09/2022 - 10/2015
5	CytokinesIBA 01/2021 - 10/2005
4	AntigensIBA 12/2021 - 10/2017
4	Glycoproteins (Glycoprotein)IBA 01/2021 - 03/2003
4	Chemokine ReceptorsIBA 11/2006 - 01/2003
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2021
3	EnzymesIBA 01/2022 - 10/2015
3	Nucleic AcidsIBA 05/2021 - 01/2017
3	VaccinesIBA 01/2021 - 11/2020
2	InterferonsIBA 03/2024 - 12/2023
2	Angiotensin-Converting Enzyme 2IBA 09/2022 - 01/2022
2	Chewing Gum (Chewing Gums)IBA 01/2022 - 01/2022
2	RNA (Ribonucleic Acid)IBA 12/2021 - 01/2021
2	Nicotine FDA Link 12/2020 - 01/2019
2	SmokeIBA 12/2020 - 01/2019
2	Circular DNAIBA 05/2019 - 01/2019
2	NeurotoxinsIBA 10/2016 - 10/2015
2	Rifampin (Rifampicin)FDA LinkGeneric 07/2014 - 06/2014
2	plerixafor FDA Link 12/2008 - 09/2002
2	Viral Envelope ProteinsIBA 11/2006 - 01/2003
1	CelluloseIBA 08/2023
1	purineIBA 01/2023
1	fludarabineIBA 01/2023
1	entecavir FDA Link 01/2023
1	nelarabine (506U78)FDA Link 01/2023
1	Histone Deacetylase InhibitorsIBA 01/2023
1	NucleosidesIBA 01/2023
1	Pepsin A (Pepsin)IBA 12/2022
1	Prostaglandins DIBA 12/2022
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 09/2022
1	PowdersIBA 01/2022
1	Interleukin-2 (IL2)IBA 12/2021
1	Interleukin-18 (Interleukin 18)IBA 12/2021
1	Protons (Proton)IBA 12/2021
1	Sirolimus (Rapamycin)FDA Link 12/2021
1	InterleukinsIBA 12/2021
1	Interleukin-1 (Interleukin 1)IBA 12/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2021
1	hexanoic acid (hexanoate)IBA 03/2021
1	propionic acid (potassium propionate)IBA 03/2021
1	Volatile Fatty AcidsIBA 03/2021
1	LipopolysaccharidesIBA 03/2021
1	C-Reactive ProteinIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Amino Acids FDA Link 01/2021
1	Atorvastatin (Lipitor)FDA Link 01/2021
1	Varenicline (Chantix)FDA Link 01/2019
1	efavirenz (Sustiva)FDA Link 01/2019
1	CD4 Antigens (CD4 Antigen)IBA 01/2019
1	Carbon MonoxideIBA 01/2019
1	GlucocorticoidsIBA 10/2018
1	Formaldehyde (Formol)FDA Link 01/2018

Therapy/Procedure

9	Therapeutics 09/2022 - 12/2009
4	Art Therapy 01/2022 - 10/2015
3	Lung Transplantation 12/2022 - 09/2012
3	Highly Active Antiretroviral Therapy (HAART) 03/2014 - 01/2008
2	Organ Transplantation 02/2024 - 01/2019
2	Length of Stay 05/2015 - 07/2014
1	Periodontics 01/2022
1	Microbubbles 12/2021
1	Aftercare (After-Treatment) 01/2021
1	Immunotherapy 01/2020
1	Transplantation 11/2019
1	Stethoscopes 02/2019